This HTML5 document contains 136 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n8http://dx.doi.org/10.1007/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q47970691
rdf:type
wikibase:Item
schema:description
2017年学术文章 article scientific scientific article published on 2 March 2017 2017年の論文 wetenschappelijk artikel vitenskapelig artikkel vedecký článok 2017年學術文章 articolo scientifico artikulong pang-agham 2017年學術文章 مقالة علمية نشرت في 2 مارس 2017 artikel ilmiah 2017年学术文章 scientific article published on 2 March 2017 vetenskaplig artikel ২ মার্চ ২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ vědecký článek სამეცნიერო სტატია article científic научни чланак tudományos cikk 2017年學術文章 artigo científico наукова стаття, опублікована в березні 2017 videnskabelig artikel 2017 nî lūn-bûn artykuł naukowy 2017年学术文章 scientific article published on 2 March 2017 article scientifique научная статья 2017년 논문 artículo científico publicado en 2017 2017年学术文章 naučni članak artikull shkencor artículu científicu επιστημονικό άρθρο bilimsel makale bài báo khoa học 2017年學術文章 מאמר מדעי artigo científico 2017年学术文章 tieteellinen artikkeli artigo científico articol științific научна статия teaduslik artikkel scienca artikolo บทความทางวิทยาศาสตร์ vitskapeleg artikkel мақолаи илмӣ научни чланак 2017 թվականի մարտի 2-ին հրատարակված գիտական հոդված 2017年学术文章 wissenschaftlicher Artikel 2017年學術文章
p:P577
wds:Q47970691-E3F116E8-0307-4B77-9F5A-96FB223222C7
wdt:P577
2017-03-02T00:00:00Z
p:P2860
wds:Q47970691-D61304C4-1096-4CAB-A748-9ED3E168F6A3 wds:Q47970691-D8921561-9C6C-4C6A-BA9D-BB9AE34CE0C0 wds:Q47970691-E25622FD-668D-49F7-B5BF-DDB292AD892B wds:Q47970691-BE779BF0-520B-4CC8-B194-AF085D5AB2F1 wds:Q47970691-C0FC1A3F-B50A-4904-A1E0-D7DB0C8D8CA2 wds:Q47970691-CCF8CFB1-6201-45E0-B21D-B9C175953E1E wds:Q47970691-E5629B12-7D65-47B8-8D52-398CDEFAE515 wds:Q47970691-E5852914-3215-452F-9999-63E6A8FA6107 wds:Q47970691-E755F3EA-EB68-4072-BA8E-0B2BDFE19090 wds:Q47970691-E8D6FCF9-703A-4E96-8975-D174C7A3C2B3 wds:Q47970691-44DE9DE2-BF29-467F-A5F6-0DF1B29512B5 wds:Q47970691-6AF083B2-7C40-4C9E-86A9-26BA05F199C6 wds:Q47970691-9F299A04-1781-4403-AA74-F542FD235735 wds:Q47970691-BC9F3DE3-EDE1-4591-B323-920A412E017C wds:Q47970691-6B940356-C9DB-479C-ABC3-C495E7F15CE8
wdt:P2860
wd:Q36868373 wd:Q40749335 wd:Q37514466 wd:Q37320282 wd:Q45000474 wd:Q42090806 wd:Q80861464 wd:Q39048818 wd:Q35102134 wd:Q30811550 wd:Q53086305 wd:Q84916829 wd:Q36064093 wd:Q33724981 wd:Q27319973
p:P2093
wds:Q47970691-F76F902F-D385-4A6A-8898-0DEF5403B008 wds:Q47970691-EE7555DB-8BFB-4635-B649-B7076E43A95E wds:Q47970691-0055782A-4CDF-4A23-B017-FE646BADC301 wds:Q47970691-139CB66D-777F-499F-8384-7D7220DEC52C wds:Q47970691-3BB539F8-50EB-41D5-8CE6-06382A570781 wds:Q47970691-90C73B2C-7BDD-4932-A09C-5094F2E01EF2
wdt:P2093
René-Marc Flipo Laurène Norberciak Eric Houvenagel Peggy Philippe Marie Desplats Germain Jelin
rdfs:label
Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
skos:prefLabel
Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
schema:name
Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
p:P50
wds:Q47970691-BA70464D-D829-421F-B37E-A2E87AC1CBEF wds:Q47970691-D584C5B4-5682-4F95-8DAE-465DAFB8404F
wdt:P50
wd:Q59681834 wd:Q56419836
p:P1476
wds:Q47970691-13812BBB-B4C0-4FCD-8AA7-90200E3AAEFE
wdt:P1476
Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
p:P304
wds:Q47970691-EB347181-E268-4997-A05B-5EB558C66C0A
wdt:P304
1395-1400
p:P31
wds:Q47970691-1FC3A79F-339B-4623-86AA-E49E534ECBB3
wdt:P31
wd:Q13442814
p:P921
wds:Q47970691-96604266-7EAF-4D45-9B97-31BA12321950 wds:Q47970691-1347C37E-A82B-4C89-A458-E98132267D89
wdt:P921
wd:Q747810 wd:Q425154
p:P698
wds:Q47970691-95B8758F-0579-4267-BFA5-6A8D06102E70
wdtn:P698
n11:28255739
wdt:P698
28255739
p:P1433
wds:Q47970691-0C1C8026-F6EC-4A36-A256-4F2EDF52CA2C
wdt:P1433
wd:Q15754927
p:P433
wds:Q47970691-EF9E8CAA-9ABD-4D7E-A2F7-15E50DB29492
p:P478
wds:Q47970691-791FF690-2C78-46EF-9F40-03725A38C66E
wdt:P433
6
wdt:P478
36
p:P356
wds:Q47970691-1E335A50-7C05-4302-94BC-033D32EC2695
wdtn:P356
n8:S10067-017-3587-8
wdt:P356
10.1007/S10067-017-3587-8